Rifaximin

Category
Systemic Antibacterial
Product code
80621-81-4

Rifaximin is a broad-spectrum, non-absorbable antibiotic active pharmaceutical ingredient widely used for the treatment of gastrointestinal infections, including traveler’s diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D). By inhibiting bacterial RNA synthesis, Rifaximin reduces pathogenic bacterial load in the gut while maintaining minimal systemic absorption, providing targeted therapy with a favorable safety profile. Pharmaceutical companies formulate Rifaximin into oral tablets and granules for suspension, ensuring convenient and precise dosing for adult and pediatric patients.

Common Rifaximin Uses and Treated Conditions

  • Traveler’s Diarrhea – Reduces severity and duration of acute bacterial diarrhea.
  • Hepatic Encephalopathy – Decreases ammonia-producing gut bacteria to prevent encephalopathy episodes.
  • Irritable Bowel Syndrome with Diarrhea (IBS-D) – Helps manage gastrointestinal symptoms and improve quality of life.
  • Gastrointestinal Infection Management – Targets localized bacterial overgrowth and infections in the intestine.

Why Choose Cambrex as Your Generic API Manufacturer?

As a leading generic API supplier, Cambrex manufactures Rifaximin API in cGMP-compliant facilities, ensuring every batch meets stringent global quality and regulatory standards. Our technical expertise, robust quality systems, and proven regulatory track record empower clients to accelerate development timelines and achieve successful market approvals. We prioritize transparency, reliability, and scientific rigor at every stage of the supply chain making us your trusted generic API manufacturer.

For detailed chemical information on Rifaximin, visit the official CAS website.

If you’d like more information or to request a sample, contact our Generic API team today.

Rifaximin

Cambrex your API partner

Cambrex are a leading global supplier of generic APIs. From our sites in Italy, Sweden, and the USA, we work with generic drug companies well in advance of drug patent expiration, using high quality, non-patent-infringing processes to manufacture APIs.

Contact us